PD‐1/PD‐L1 inhibitors‐based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies

PD‐1/PD‐L1 inhibitors‐based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies

Abstract With the widespread use of PD‐1/PD‐L1 monoclonal antibodies (mAbs) in the treatment of multiple malignant tumors, they were also gradually applied to advanced renal cell carcinoma (aRCC). Nowadays, multiple PD‐1/PD‐L1 mAbs, such as nivolumab, avelumab, and pembrolizumab, have achieved consi...

Full description

Bibliographic Details
Main Authors: Lei Ding, Hui yu Dong, Tian ren Zhou, Yu hao Wang, Tao Yan, Jun chen Li, Zhong yuan Wang, Jie Li, Chao Liang
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:Cancer Medicine
Subjects:
advanced renal cell carcinoma
cellular immunity
combination therapy
fundamental mechanisms
PD‐1
PD‐L1 inhibitor
Online Access:https://doi.org/10.1002/cam4.4190

Internet

https://doi.org/10.1002/cam4.4190

Similar Items